ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.
Demonstrates 100% Completion of Planned Treatment Cycles.
Immix Biopharma, Inc. Wed, January 19, 2022.
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating...
Revive Therapeutics Updates, on Phase III Clinical Trial!
Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Revive Therapeutics Provides Update on...
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
TORONTO, Jan. 17, 2022 (GLOBE...
Adding Immix Biopharma (IMMX) to 2022 Biotech 12 Pack List.
Added to 12 Biotech Stocks we Expect to Double List.
The Original Biotech 6-Pack from 2020, is Growing to a 12-Pack!
Okay, here's our second...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma (RDHL), AI Pharma (Private), Apilli Thera...
Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught flat-footed upon potential approval, Revive is...
Latest article
Annette L. Redmond Joins Strategic Advisory Board at Sekur Private Data (SWISF).
Former U.S. State Department Deputy Assistant Secretary
Decorated intelligence and cybersecurity executive with four decades of U.S. government leadership joins Sekur to advise on secure...
10X Alerts: Sekur Private Data (SWISF) Pushes SekurOne Closer to Market With First International...
Sekur has completed its first domestic and international encrypted calls on SekurOne and launched the platform’s voice, email, messenger, and VPN capabilities on Android...
Could a Record El Niño Ignite the Next Vaccine Trade?
Chikungunya, Dengue Fever, Rift Valley Fever and Zika
The Coming El Niño: An Overlooked Catalyst for Vaccine Stocks?
Investors obsess over interest rates, tariffs and AI....
